129 related articles for article (PubMed ID: 16000957)
1. Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse.
Triozzi PL; Aldrich W; Allen KO; Carlisle RR; LoBuglio AF; Conry RM
J Immunother; 2005; 28(4):382-8. PubMed ID: 16000957
[TBL] [Abstract][Full Text] [Related]
2. Development of a polynucleotide vaccine from melanoma antigen recognized by T cells-1 and recombinant protein from melanoma antigen recognized by T cells-1 for melanoma vaccine clinical trials.
Lee SW; Li H; Strong TV; Moore SE; Conry RM
J Immunother; 2000; 23(3):379-86. PubMed ID: 10838667
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma.
Weber J; Boswell W; Smith J; Hersh E; Snively J; Diaz M; Miles S; Liu X; Obrocea M; Qiu Z; Bot A
J Immunother; 2008; 31(2):215-23. PubMed ID: 18481391
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma.
Wang F; Bade E; Kuniyoshi C; Spears L; Jeffery G; Marty V; Groshen S; Weber J
Clin Cancer Res; 1999 Oct; 5(10):2756-65. PubMed ID: 10537339
[TBL] [Abstract][Full Text] [Related]
5. Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen.
Rosenberg SA; Yang JC; Sherry RM; Hwu P; Topalian SL; Schwartzentruber DJ; Restifo NP; Haworth LR; Seipp CA; Freezer LJ; Morton KE; Mavroukakis SA; White DE
Hum Gene Ther; 2003 May; 14(8):709-14. PubMed ID: 12804135
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A.
Cormier JN; Salgaller ML; Prevette T; Barracchini KC; Rivoltini L; Restifo NP; Rosenberg SA; Marincola FM
Cancer J Sci Am; 1997; 3(1):37-44. PubMed ID: 9072306
[TBL] [Abstract][Full Text] [Related]
7. Improved humoral and cellular immune responses against the gp120 V3 loop of HIV-1 following genetic immunization with a chimeric DNA vaccine encoding the V3 inserted into the hepatitis B surface antigen.
Fomsgaard A; Nielsen HV; Bryder K; Nielsen C; Machuca R; Bruun L; Hansen J; Buus S
Scand J Immunol; 1998 Apr; 47(4):289-95. PubMed ID: 9600309
[TBL] [Abstract][Full Text] [Related]
8. Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen.
Smithers M; O'Connell K; MacFadyen S; Chambers M; Greenwood K; Boyce A; Abdul-Jabbar I; Barker K; Grimmett K; Walpole E; Thomas R
Cancer Immunol Immunother; 2003 Jan; 52(1):41-52. PubMed ID: 12536239
[TBL] [Abstract][Full Text] [Related]
9. Routes of plasmid DNA vaccination that prime murine humoral and cellular immune responses.
Böhm W; Mertens T; Schirmbeck R; Reimann J
Vaccine; 1998; 16(9-10):949-54. PubMed ID: 9682342
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients.
Conry RM; Curiel DT; Strong TV; Moore SE; Allen KO; Barlow DL; Shaw DR; LoBuglio AF
Clin Cancer Res; 2002 Sep; 8(9):2782-7. PubMed ID: 12231517
[TBL] [Abstract][Full Text] [Related]
11. Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates.
McCluskie MJ; Brazolot Millan CL; Gramzinski RA; Robinson HL; Santoro JC; Fuller JT; Widera G; Haynes JR; Purcell RH; Davis HL
Mol Med; 1999 May; 5(5):287-300. PubMed ID: 10390545
[TBL] [Abstract][Full Text] [Related]
12. Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients.
Xu Y; Theobald V; Sung C; DePalma K; Atwater L; Seiger K; Perricone MA; Richards SM
J Transl Med; 2008 Oct; 6():61. PubMed ID: 18945350
[TBL] [Abstract][Full Text] [Related]
13. Modulation of gene-gun-mediated Th2 immunity to hepatitis B surface antigen by bacterial CpG motifs or IL-12.
Schirmbeck R; Reimann J
Intervirology; 2001; 44(2-3):115-23. PubMed ID: 11509872
[TBL] [Abstract][Full Text] [Related]
14. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
[TBL] [Abstract][Full Text] [Related]
15. Cationic transfersomes based topical genetic vaccine against hepatitis B.
Mahor S; Rawat A; Dubey PK; Gupta PN; Khatri K; Goyal AK; Vyas SP
Int J Pharm; 2007 Aug; 340(1-2):13-9. PubMed ID: 17446015
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with a fusion DNA vaccine encoding hepatitis B surface antigen fused to the extracellular domain of CTLA4 enhances HBV-specific immune responses in mice: implication of its potential use as a therapeutic vaccine.
Zhou C; Peng G; Jin X; Tang J; Chen Z
Clin Immunol; 2010 Nov; 137(2):190-8. PubMed ID: 20692873
[TBL] [Abstract][Full Text] [Related]
17. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens.
Rosenberg SA; Zhai Y; Yang JC; Schwartzentruber DJ; Hwu P; Marincola FM; Topalian SL; Restifo NP; Seipp CA; Einhorn JH; Roberts B; White DE
J Natl Cancer Inst; 1998 Dec; 90(24):1894-900. PubMed ID: 9862627
[TBL] [Abstract][Full Text] [Related]
18. Plasmids enriched with CpG motifs activate human peripheral blood mononuclear cells in vitro and enhance th-1 immune responses to hepatitis B surface antigen in mice.
Chen Z; Cao J; Liao X; Ke J; Zhu S; Zhao P; Qi Z
Viral Immunol; 2011 Jun; 24(3):199-209. PubMed ID: 21668361
[TBL] [Abstract][Full Text] [Related]
19. Advantage of gene gun-mediated over intramuscular inoculation of plasmid DNA vaccine in reproducible induction of specific immune responses.
Yoshida A; Nagata T; Uchijima M; Higashi T; Koide Y
Vaccine; 2000 Mar; 18(17):1725-9. PubMed ID: 10699319
[TBL] [Abstract][Full Text] [Related]
20. Engineering enhancement of the immune response to HBV DNA vaccine in mice by the use of LIGHT gene adjuvant.
Zhang Y; Jiang W; Fan Y; Wen J; Hao W; Qian M
J Virol Methods; 2008 Nov; 153(2):142-8. PubMed ID: 18722475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
